Nexalin Technology, Inc. 1Q 2026: Revenue $14.95K, EPS ($0.11) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Nexalin Technology, Inc. reported a revenue of $14.95K for Q1 2026, down 63.5% from $41.02K a year prior, with a net loss of $2.1M and diluted EPS of ($0.11). The decline in revenue was attributed to lower international equipment sales, although a shift towards higher-margin licensing fees improved gross margins. The company initiated a pivotal insomnia trial and reported increased operating expenses, raising concerns about its financial viability.
Nexalin Technology, Inc. reported first-quarter 2026 results with revenue down to $14.95K from $41.02K a year earlier and a net loss of ($2.1M), or diluted EPS of ($0.11).
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $14.95K | $41.02K | (63.5%) |
| Net income² | ($2.1M) | ($1.99M) | (5.5%) |
| Diluted EPS³ | ($0.11) | ($0.15) | 26.7% |
¹ Reported as “Revenues, net (includes related party of $ 0 and $ 3,583 for the three months ended March 31, 2026 and March 31, 2025, respectively)”. ² Reported as “Net loss”. ³ Reported as “loss per share attributable to common stockholders - Basic and Diluted”.
Business Highlights
- Revenue trend: Revenues declined about 64% year over year to approximately $15K in Q1 2026, driven by lower international equipment sales.
- Channel shift: The company reported a shift in mix toward higher‑margin licensing fees versus device and equipment sales, which improved gross margin dynamics.
- Product and regulatory milestones: FDA accepted a Q‑Submission for Gen‑2 SYNC, and the Gen‑3 HALO pivotal insomnia trial was initiated with a UK CRO statement of work.
- Operating outlook: Operating expenses rose modestly due to higher professional fees and increased headcount; cash burn to fund trials and development continues, creating material doubt about going concern.
Original SEC Filing: Nexalin Technology, Inc. [ NXL ] - 10-Q - May. 08, 2026